Skip to content
lsd.com
Unknown statusNot applicable

Using a Low Dose of Ketamine vs. Active Placebo in Treating Severe Depression and Suicide

NCT03666390 · Taipei Veterans General Hospital, Taiwan

Closed to entry
Status
Not accepting participants
Not applicable
Phase
48
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

Depression and suicide are two leading mental health and public health issues in Taiwan. However, until now, the optimal treatment for refractory depression and suicide is still lacking. Previous USA studies suggested a low dose NMDA antagonist Ketamine infusion can significantly reduce depression and suicide. In our study, we firstly investigate the anti-suicide and anti-depressive effects of ketamine in Taiwan. If we can find the similar antidepressant and anti-suicide of ketamine in Taiwanese, this result will have a great influence in the current suicide and depression prevention programs.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Reduction rate of suicide symptom

    Measured over 4 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 14 days.

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

20 Years to 65 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: 1. Major depression including unipolar and bipolar depression, according to DSM-IV criteria and MINI (MiniInternational Neuropsychiatric Interview;MINI) diagnostic interview. 2. Age ≧ 20y/o \< 65 y/o 3. voluntary patients with signed informed consent proved by institutional review board (IRB) Exclusion Criteria: 1. Major medical conditions (e.g., head injury, epilepsy, severe renal diseases and cancer). 2. Other axis I psychiatric disorders such as schizophrenia, delusional disorder, organic brain syndrome, and dementia. 3. Pregnancy. 4. Substance abuse in previous 6 months such as cocaine, marijuana, opium, ketamine, PCP (phencyclidine)。 5. Current use of NMDA receptor antagonist (Amantadine, Rimantadine, Lamotrigine, Memantine, Dextromethorphan) 6. Alcohol abuse / dependence within 6 months. 7. Attempt suicide in hospital.

Where

1 study site

FacilityCityRegionCountry
Taipei Veterans General HospitalTaipei—Taiwan

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT03666390 on ClinicalTrials.gov →

Last updated in the registry 2018-09-19. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits

Substance

All 2 trials from Taipei Veterans General Hospital, Taiwan →